AQP4+NMOSD (n=36) | RRMS (n=60) | p value | |
ΔEDSS (MRI-2 – MRI-1) | 0.0 (0.0) (–2.0–3.5) | 0.0 (0.19) (–3.0–2.5) | 0.81 |
Years from MRI-1 to MRI-2 | 3.1 (2.5) (1.0–6.3) | 2.2 (1.8) (1.0–6.1) | 0.045* |
ARR between MRI-1 and MRI-2 | 0.0 (0.0) (0.0–0.88) | 0.0 (0.0) (0.0–1.5) | 0.56 |
At MRI-1 | |||
ICV*10-3 (mL) | 1.3 (0.12) (1.2–1.6) | 1.4 (0.14) (1.1–1.7) | 0.034* |
NLV (mL) | 1.0 (5.2) (0.0–33.2) | 6.4 (10.3) (0.45–46.7) | <0.001* |
NGV*10-3 (mL) | 0.43 (0.063) (0.32–0.49) | 0.44 (0.058) (0.32–0.50) | 0.47 |
NWV*10-3 (mL) | 0.31 (0.029) (0.22–0.34) | 0.29 (0.033) (0.23–0.34) | 0.007* |
NBV*10-3 (mL) | 0.75 (0.070) (0.62–0.81) | 0.73 (0.085) (0.59–0.80) | 0.61 |
At MRI-2 | |||
ICV*10-3 (mL) | 1.3 (0.12) (1.2–1.6) | 1.4 (0.14) (1.1–1.7) | 0.068 |
NLV (mL) | 2.4 (9.0) (0.0–142) | 6.6 (10.3) (0.0–187) | 0.019* |
NGV*10-3 (mL) | 0.43 (0.053) (0.31–0.49) | 0.44 (0.060) (0.32–0.50) | 0.5 |
NWV*10-3 (mL) | 0.31 (0.033) (0.22–0.34) | 0.29 (0.029) (0.22–0.34) | 0.007* |
NBV*10-3 (mL) | 0.74 (0.074) (0.60–0.80) | 0.72 (0.088) (0.58–0.80) | 0.43 |
Annualised atrophy rate | |||
NGV (%) | 0.50 (1.1) (–2.4–4.9) | 0.36 (1.4) (–2.5–5.7) | 0.96 |
NWV (%) | 0.21 (1.5) (–6.2–4.5) | 0.33 (2.0) (–3.6–6.3) | 0.72 |
NBV (%) | 0.47 (0.75) (–0.57–3.0) | 0.48 (0.85) (–1.3–3.4) | 0.47 |
Data are presented as median number (%) or (IQR) (range). *p<0.05.
Annualised atrophy rate of X is defined as follows: , X= NGV, NWV or NBV.
ΔEDSS= EDSS at MRI-2 minus EDSS at MRI-1.
AQP4+NMOSD, anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder disease; EDSS, Kurtzke’s Expanded Disability Status Scale; ICV, intracranial volume; NBV, normalised brain volume; NGV, normalised grey matter volume; NLV, normalised lesion volume; NWV, normalised white matter volume.